SCHEMBL2925227

SCHEMBL2925227

CCCN1[C@H](C)CN(c2ccc(Cl)c(C(F)(F)F)c2)C[C@@H]1C

nearest known ligand 0.52

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.52
NOTUM Q6P988 17/20 0.47
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2925230 1.00 DPP4 (0.52) DPP4NOTUMTSHRSMN1; SMN2
SCHEMBL2928605 0.86 NOTUM (0.46) DPP4NOTUM
SCHEMBL2928601 0.86 NOTUM (0.46) DPP4NOTUM
SCHEMBL2929745 0.84 DPP4 (0.47) DPP4NOTUMSMN1; SMN2
SCHEMBL2929747 0.84 DPP4 (0.47) DPP4NOTUMSMN1; SMN2
SCHEMBL2922525 0.77 DPP4 (0.52) DPP4NOTUMSMN1; SMN2
SCHEMBL7132782 0.76 ALDH1A1 (0.55) NOTUMTSHRSMN1; SMN2
SCHEMBL7132786 0.76 ALDH1A1 (0.55) NOTUMTSHRSMN1; SMN2
SCHEMBL20080888 0.72 NOTUM (0.58) DPP4NOTUMSMN1; SMN2
SCHEMBL8320138 0.72 SIRT6 (0.59) DPP4NOTUMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE41315-E1 Modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB (DE) 2010-05-04 US disclosed
US-6924374-B2 Central nervous system disorders; psychological disorders A. CARLSSON RESEARCH AB (SE) 2005-08-02 US disclosed
EP-1419773-A2 4-Phenylpiperidine derivatives as modulators of dopamine neurotransmission A. Carlsson Research AB (SE) 2004-05-19 EP disclosed
US-20030004169-A1 Modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2003-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004169-A1 Modulators of dopamine neurotransmission OPRD1, OPRK1, OPRM1 DPP4 4249/4885NOTUM 3910/4885TSHR 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.